Login to Your Account

Biogen Idec Licenses PAH Drug From MondoBiotech

By Karen Pihl-Carey

Friday, September 15, 2006
Licensing a pulmonary arterial hypertension program from a Swiss company, Biogen Idec Inc. has stepped into a new therapeutic area to address a frequently undiagnosed disease that may affect up to 200,000 people worldwide. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription